Unfavorable clinical implications for hypermethylation of RUNX3 in patients with salivary gland adenoid cystic carcinoma

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 349-357

  Ge, Ming Hua ^a   Chen, Chao ^a   Xu, Jia Jie ^a   Ling, Zhi Qiang ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Disease free survival; Human salivary gland adenoid cystic carcinoma; Methylation; Real time methylation speciflc PCR; Runt related transcription factor 3; Western blotting

Indexed keywords

TRANSCRIPTION FACTOR RUNX3;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERMETHYLATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORAL SURGERY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; SALIVARY GLAND ADENOID CYSTIC CARCINOMA; SALIVARY GLAND CARCINOMA; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, ADENOID CYSTIC; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; YOUNG ADULT;

EID: 79958228953     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1282     Document Type: Article

References (58)

1. Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, Vilos GA, Douzinas EE and Patsouris E: Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol 41: 328-335, 2005.
2. Sung MW, Kim KH, Kim JW, Min YG, Seong WJ, Roh JL, Lee SJ, Kwon TK and Park SW: Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 129: 1193-1197, 2003. (Pubitemid 37433155)
3. Spiro RH, Huvos AG and Strong EW: Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128: 512-520, 1974.
4. Kim KH, Sung MW, Chung PS, Rhee CS, Park CI and Kim WH: Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 120: 721-726, 1994.
5. Spiro RH, Huvos AG and Strong EW: Adenoid cystic carcinoma: factors influencing survival. Am J Surg 138: 579-583, 1979. (Pubitemid 10250075)
6. Garden AS, Weber RS, Morrison WH, Ang KK and Peters LJ: The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 32: 619-626, 1995.
7. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ and Million RR: Managements of minor salivary gland carcinomas. Int J Radiat Oncol Biol Phys 35: 443-454, 1996. (Pubitemid 26242891)
8. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002. (Pubitemid 34327521)
9. Ito Y: Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 23: 4198-4208, 2004.
10. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, Ushijima T, Kim WJ, Ito Y and Bae SC: RUNX3 suppresses gastric epithelial cell growth by inducing p21[WAF1/Cip1] expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25: 8097-8107, 2005. (Pubitemid 41263003)
11. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG and Ito Y: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750, 2005. (Pubitemid 41297249)
12. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y and Bae SC: RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65: 9347-9354, 2005. (Pubitemid 41508002)
13. Blyth K, Cameron ER and Neil JC: The RUNX3 genes: gain or loss of function in cancer. Nat Rev Cancer 5: 376-387, 2005. (Pubitemid 40637829)
14. Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T and Nakao A: Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int 25: 380-388, 2005.
15. Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS and Mok SC: RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol 112: 325-330, 2009.
16. -/- gastric epithelial cells differentiate into intestinal type cells. Biochem Biophys Res Commun 321: 58-64, 2004. (Pubitemid 39055605)
17. Miyasono K, Suzuki H and Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 94: 230-234, 2003. (Pubitemid 36575887)
18. Fukamaclii H: Runx3 controls growth and differentiation of gastric epithelial cells in mammals. Dev Growth Differ 48: 1-13, 2006.
19. Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Frenkel EP, Minna JD, Fujisawa T and Gazdar AF: DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 93: 1029-1037, 2005. (Pubitemid 41548398)
20. Tozawa T, Tamura G, Honda T, Nawata S, Kimura W, Makino N, Kawata S, Sugai T, Suto T and Motoyama T: Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 95: 736-740, 2004. (Pubitemid 39335093)
21. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T, Kohama G and Tokino T: Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8: 3164-3171, 2003.
22. Yang Q, Zage P, Kasan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A and Cohn SL: Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 10: 8493-8500, 2004. (Pubitemid 40053415)
23. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation down-regulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23: 6736-6742, 2004. (Pubitemid 39280005)
24. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y and Sukumar S: RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520, 2006. (Pubitemid 44085605)
25. Li J, El-Nagaar A and Mao L: Promoter methylation of P16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 104: 771-776, 2005.
26. Maruya S, Kurotaki H, Wada R, Saku T, Shinkawa H and Yagihashi S: Promoter methylation and protein expression of the E-cadherin gene in the clinicopathologic assessment of adenoid cystic carcinoma. Mod Pathol 17: 637-645, 2004. (Pubitemid 38715485)
27. Zhang CY, Mao L, Li L, Tian Z, Zhou XJ, Zhang ZY and Li J: Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer 110: 87-95, 2007. (Pubitemid 46992031)
28. Guan XF, Qiu WL and He RG: The selection of high lung metastasis salivary adenoid cystic carcinoma clone. Chin J Stomatol 3: 74-77, 1996.
29. He RG, Zhang XS and Zhou XJ: The establishment of cell lines of adenoid cystic carcinoma of human salivary glands (ACC-2, ACC-3) and a study of morphology. West China J Stomatol 6: 1-4, 1988.
30. Wittekind C, Compton CC, Greene FL and Sobin LH: TNM residual tumor classification revisited. Cancer 94: 2511-2516, 2002. (Pubitemid 34457134)
31. Ling ZQ, Sugihara H, Tatsuta T, Mukaisho K and Hattori T: Optimization of comparative expressed sequence hybridization for genome-wide expression profiling at chromosome level. Cancer Genet Cytogenet 175: 144-153, 2007. (Pubitemid 46855936)
32. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S and Motoyama T: Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci 94: 360-364, 2003. (Pubitemid 36626369)
33. Homma N, Tamura G, Honda T, Matsumoto Y, Nishizuka S, Kawata S and Motoyama T: Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci 97: 51-56, 2006. (Pubitemid 43257027)
34. Noble JE and Bailey MJ: Quantitation of protein. Meth Enzymol 463: 73-95, 2009.
35. Ehrlich M: The controversial denouement of vertebrate DNA methylation research. Biochemistry 70: 568-575, 2005.
36. Pufulete M, Al-Ghnaniem R, Rennie JA, Appleby P, Harris N, Gout S, Emery PW and Sanders TA: Influence of folate status on genomic DNA methylation in colonic mucosa of subjects without colorectal adenoma or cancer. Br J Cancer 92: 838-842, 2005. (Pubitemid 40462627)
37. Kim TY, Jong HS, Jung Y, Kim TY, Kang GH and Bang YJ: DNA hypermethylation in gastric cancer. Aliment Pharmacol Ther 20: 131-142, 2004. (Pubitemid 39120285)
38. Cameron EE, Bachman KE, Myöhänen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999. (Pubitemid 29036293)
39. Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L, Le X, Yao J, Wu TT, Huang S and Xie K: Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65: 4809-4816, 2005. (Pubitemid 40740819)
40. Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Yazumi S, Yamagishi H, Okanoue T, Chiba T and Hagiwara A: Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11: 6479-6788, 2005.
41. Derynck R, Akhurst RJ and Balmain A: TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001. (Pubitemid 32952643)
42. Fukamachi H and Ito K: Growth regulation of gastric epithelial cells by Runx3. Oncogene 23: 4330-4335, 2004. (Pubitemid 38758598)
43. Ito Y and Miyazono K: RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr Opin Genet Dev 13: 43-47, 2003. (Pubitemid 36143926)
44. Torquati A, O'rear L, Longobardi L, Spagnoli A, Richards WO and Daniel Beauchamp R: RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery 136: 310-316, 2004. (Pubitemid 39037670)
45. Park SR, Lee EK, Kim BC and Kim PH: p300 cooperates with Smad3/4 and Runx3 in TGFbeta1-induced IgA isotype expression. Eur J Immunol 33: 3386-3392, 2003.
46. Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS and Lian JB: Integration of RUNX and Smad regulatory signals at transcriptionally active subnuclear site. Proc Natl Acad Sci USA 99: 8048-8053, 2002. (Pubitemid 34651003)
47. Tsunematsu T, Kudo Y, Iizuka S, Ogawa I, Fujita T, Kurihara H, Abiko Y and Takata T: RUNX3 has an oncogenic role in head and neck cancer. PLoS One 4: e5892, 2009.
48. So K, Tamura G, Honda T, Homma N, Waki T, Togawa N, Nishizuka S and Motoyama T: Multiple tumor suppressor genes are increasingly methylated with age in non-neoplastic gastric epithelia. Cancer Sci 97: 1155-1158, 2006. (Pubitemid 44430640)
49. Chen W, Gao N, Shen Y and Cen JN: Hypermethylation down-regulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 25: 823-831, 2010.
50. Tamura G, So K, Miyoshi H, Honda T, Nishizuka S and Motoyama T: Quantitative assessment of gene methylation in neoplastic and non-neoplastic gastric epithelia using methylation-specific DNA microarray. Pathol Int 59: 895-899, 2009.
51. Gao F, Huang C, Lin M, Wang Z, Shen J, Zhang H, Jiang L and Chen Q: Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res Clin Oncol 135: 739-747, 2009.
52. Nomoto S, Kinoshita T, Mori T, Kato K, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Adverse prognosis of epigenetic inactivation in RUNX3 gene in 1p36 in human pancreatic cancer. Br J Cancer 98: 1690-1695, 2008. (Pubitemid 351684677)
53. Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T and Mori M: Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 15: 129-135, 2006.
54. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC and Kim WJ: Methylation of the RUNX3 promoter as a potential prognoistic marker for bladder tumor. J Urol 180: 806-807, 2008.
55. Chuang LS and Ito Y: RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29: 2605-2615, 2010.
56. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC and Kim WJ: Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol 180: 1141-1145, 2008.
57. Jiang Y, Tong D, Lou G, Zhang Y and Geng J: Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology 75: 244-251, 2008. (Pubitemid 351918429)
58. He JF, Ge MH, Zhu X, Chen C, Tan Z, Li YN and Gu ZY: Expression of RUNX3 in salivary adenoid cystic carcinoma: Implications for tumor progression and prognosis. Cancer Sci 99: 1334-1340, 2008. (Pubitemid 351761721)